Healthcare reform requiring wider access and enterprise sharing of patient images and records are making Web-based cardiology picture archiving and communication systems (PACS) a more attractive solution over traditional thick-client, server-based systems. In just the past few years there has been a departure from thick-client cardiology and radiology PACS to Web-based platforms. There are several reasons for this, including better interoperability, anywhere-anytime access, remote access to data and images, and reduction of IT burdens. Web-based systems also enable easier delivery of many healthcare reform Stage 2 meaningful use (MU) requirements. 


Finding ways to lower patient radiation dose from both medical imaging and interventional cardiology has become a major trend. However, when vendors start talking dose, it is important to realize there are no set industry standards agreed upon by manufacturers to calculate dose. For this reason, I call into question vendors’ statistics of how much their technology can lower dose by up to 20, 50 or even 80 percent.  While new technologies such as iterative reconstruction, more sensitive detectors and ECG gating do indeed lower dose, quantifying it can be a moving target. 



AngioScore Inc. announced the completion of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) Study (PATENT-C). AngioScore anticipates that preliminary data from this study will be available for presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference to be held this fall in San Francisco


Toshiba America Medical Systems Inc. has partnered with Unfors RaySafe Inc. to offer a new radiation dose monitoring and management tool for Infinix-i cardiovascular X-ray systems. The Unfors RaySafe i2 displays real-time dose exposure information, helping to make exams safer for all clinical staff.

July 22, 2013 — A new report issued by the American College of Cardiology (ACC) and developed in collaboration with 10 other professional societies provides detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous system.


T2 Biosystems announced the presentation of data strongly correlating T2Hemostat results with patients’ clinical outcomes. In 26 patients who presented with chest pain and underwent cardiac catheterization, T2HemoStat was compared to a common platelet activity assay, where T2HemoStat accurately correlated to 100 percent of bleeding event cases while the comparator did not identify bleeding events in any patients. T2HemoStat also correlated to twice the number of thrombotic cases than the comparator. These data are complemented by additional presentations that demonstrate T2MR’s ability to identify novel clot biology, which may account for previously unexplained clot behavior while providing new clinical insights into the formation and degradation of blood clots. T2HemoStat is the company’s novel system for the rapid detection of physical changes in a blood sample, identifying novel clot biology while also measuring hemostasis characteristics such as coagulation, fibrinolysis and platelet function from finger stick size, small volumes of whole blood or plasma on a single, compact instrument.

 
Subscribe Now